ストックスクリーナーアプリを入手
49.75
0.48%
-0.24
アフターアワーズ：
49.51
-0.24
-0.48%
前日終値:
$49.99
開ける：
$49.815
24時間の取引高:
3.29M
Relative Volume:
1.94
時価総額：
$5.95B
収益：
$18.47M
当期純損益:
$-589.53M
株価収益率:
-9.4582
EPS:
-5.26
ネットキャッシュフロー:
$-399.80M
1週間 パフォーマンス:
+33.20%
1か月 パフォーマンス:
+36.00%
6か月 パフォーマンス:
+13.87%
1年 パフォーマンス:
-9.36%
1日の値動き範囲:
$48.93
$51.69
1週間の範囲:
$35.22
$51.69
52週間の値動き範囲:
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
49.75 | 5.94B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Using Python tools to backtest Cytokinetics Incorporated strategies2025 Retail Activity & Safe Capital Growth Tips - Newser
Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising - MSN
Cytokinetics Incorporated stock prediction for this week2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results - Zacks Investment Research
Is Cytokinetics Incorporated stock bottoming outMarket Performance Summary & Long-Term Capital Growth Strategies - Newser
Will Cytokinetics Incorporated benefit from rate cutsInsider Selling & Risk Controlled Stock Alerts - khodrobank.com
Understanding Cytokinetics Incorporated’s price movement2025 Biggest Moves & Community Trade Idea Sharing Platform - Newser
Does Cytokinetics Incorporated show high probability of reboundJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - Newser
Predicting Cytokinetics Incorporated trend using moving averagesGDP Growth & Safe Entry Trade Reports - Newser
Can Cytokinetics Incorporated recover in the next quarterMarket Rally & Free Safe Capital Growth Stock Tips - Newser
Applying chart zones and confluence areas to Cytokinetics Incorporated2025 Year in Review & Growth Oriented Trade Recommendations - Newser
What’s next for Cytokinetics Incorporated stock pricePortfolio Profit Report & Long-Term Growth Plans - Newser
Technical signs of recovery in Cytokinetics IncorporatedMarket Sentiment Summary & Safe Entry Zone Tips - Newser
Detecting support and resistance levels for Cytokinetics IncorporatedChart Signals & High Win Rate Trade Alerts - Newser
How high can Cytokinetics Incorporated stock goJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - Newser
Real time social sentiment graph for Cytokinetics IncorporatedTrade Risk Report & Low Drawdown Trading Techniques - Newser
Cytokinetics’ Aficamten with breakthrough Phase III results - European Biotechnology Magazine
Cytokinetics Shares Jump 40.45% on Aficamten HCM Data $630M Volume Ranks 162nd - AInvest
Is Cytokinetics Incorporated on track to beat earnings2025 Key Highlights & Smart Swing Trading Techniques - khodrobank.com
Should I buy Cytokinetics Incorporated stock nowIPO Watch & Daily Profit Maximizing Trade Tips - khodrobank.com
Cytokinetics’ Aficamten Shows Head-To-Head Advantage Vs. Beta Blockers - insights.citeline.com
How to read the order book for Cytokinetics IncorporatedEarnings Recap Report & Weekly Top Gainers Alerts - Newser
Nvidia, PepsiCo, Tesla, Kraft Heinz, Constellation Brands, Cytokinetics, and More Market Movers - Barron's
Cytokinetics at Citi’s Biopharma Conference: Aficamten’s Promising Path - Investing.com
Cytokinetics Skyrockets On 'Provocative' Results In Heart Disease - Investor's Business Daily
Aficamten Bests Metoprolol in Cytokinetics' Trial for Obstructive Hypertrophic Cardiomyopathy - PharmTech
Bitcoin gains, Frontier upgraded, Cytokinetics trial results - Yahoo Finance
Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics says heart disease drug more effective than standard-of-care, shares jump - TradingView
Cytokinetics’ Aficamten: Navigating Regulatory Hurdles and Market Potential in the OHCM Space - AInvest
Cytokinetics Appoints New Director Amid Revenue Boost and Strategic Moves - StocksToTrade
Board Appointment Boosts Cytokinetics’ Growth Projections - timothysykes.com
Cytokinetics Shares are Jumping. Its Heart Drug Looks Better than Ever - Barron's
Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action? - Benzinga
Cytokinetics makes its case for heart-failure drug ahead of FDA decision, stock surges more than 40% - The Business Journals
Cytokinetics shares surge 35.66% in premarket after positive results from MAPLE-HCM III trial. - AInvest
Cytokinetics Soars 35.13% on Promising Heart Disease Data - AInvest
Is Cytokinetics Incorporated’s ROE strong enough2025 Major Catalysts & Advanced Swing Trade Entry Plans - khodrobank.com
Fed Watch: Is Cytokinetics Incorporated a top pick in the sectorCEO Change & Safe Investment Capital Preservation Plans - خودرو بانک
Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough - Stocktwits
Is Cytokinetics Incorporated forming a reversal patternJuly 2025 Review & Safe Capital Investment Plans - Newser
Pattern recognition hints at Cytokinetics Incorporated upside2025 Top Gainers & Free Weekly Watchlist of Top Performers - Newser
Multi asset correlation models including Cytokinetics IncorporatedQuarterly Trade Summary & Step-by-Step Trade Execution Guides - Newser
Risk adjusted return profile for Cytokinetics Incorporated analyzedMarket Growth Summary & Technical Pattern Based Signals - Newser
Published on: 2025-09-01 20:47:13 - khodrobank.com
Cytokinetics Incorporated stock retracement – recovery analysis2025 Investor Takeaways & Daily Stock Trend Watchlist - Newser
Will Cytokinetics Incorporated benefit from macro trendsMarket Rally & Risk Managed Investment Strategies - Newser
Custom Dashboard Highlights Cytokinetics Incorporated Price MomentumJuly 2025 Spike Watch & Low Drawdown Investment Strategies - beatles.ru
Cytokinetics’ aficamten bests beta blocker in head-to-head trial - The Pharma Letter
Cytokinetics Incorporated stock volume spike explainedQuarterly Trade Summary & Weekly Sector Rotation Insights - Newser
What the charts say about Cytokinetics Incorporated todayWeekly Trade Summary & Community Consensus Trade Signals - Newser
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
1.75%
1.11%
大文字化:
|
ボリューム (24 時間):